Shares of Alkermes Inc. dropped 9.2 percent Friday after the firm confirmed rumors in the market that its partner Eli Lilly and Co. plans to pull out of its deal to develop and commercialize AIR Inhaled Insulin, which currently is in Phase III development for diabetes. (BioWorld Today) Read More
